$OFIX

McPherron Aviva sold $34K of OFIX

McPherron Aviva (Pres, Global Ops & Qual) sold 3,670 shares of Orthofix Medical Inc. (OFIX) at $9.38 on 2026-06-18.

Original reporting
SEC EDGAR · McPherron Aviva
Published Jun 22, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Neutral
high confidence
Mentioned
$OFIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXNeutralLow
01

Why it matters

A single officer open-market sale of ~$34.4K is disclosed; it does not include new operational, financial, or regulatory information.

02

Market read

Traders may note insider activity, but the disclosed transaction size and lack of additional company-specific news suggest limited trading edge.

03

What to watch

The article does not state tax/portfolio rationale, whether the sale was part of a broader pattern, or any concurrent company news; without that context, signal quality is low.

Relevance 3/10Novelty 3/10Timing: Filed 2026-06-22; sale executed 2026-06-18.

Background

The article is an SEC Form 4 insider transaction disclosure for Orthofix Medical Inc.

Company-level read

Ticker impact

$OFIXNeutralHigh confidence
Context

Orthofix Medical insider McPherron Aviva sold 3,670 shares on 2026-06-18 at $9.38/share for ~$34.4K, per Form 4.

Expected impact

Minimal near-term impact; any effect is likely short-lived and outweighed by normal trading noise.

Evidence & confidence

The filing is a small, non-accelerated sale by an officer with no 10b5-1 plan disclosed; size is modest and does not indicate a new corporate event.

Market effects

No sector-level read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can sometimes precede negative developments, but this disclosure lacks any accompanying catalyst or guidance change.

Key entities

  • Orthofix Medical Inc.

    Company whose insider transaction is reported on Form 4.

  • McPherron Aviva

    Pres, Global Ops & Qual who sold 3,670 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXMed

Orthofix Medical Inc. Q2 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q2 2026 earnings call updates, emphasizing a shift toward distributor quality and asset utilization. Management expects 2026 net sales and EBITDA guidance to rise by $7 million, citing $12 million Medicare reimbursement restoration and $15 million European distributor benefit, partly offset by weaker smaller spine distributors. Medicare bone stimulator reimbursement was restored retroactive to May 18, 2026.

$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

$OFIXMedAI 8/10

Why is Orthofix Medical stock surging today? By Investing.com

Orthofix Medical shares rose 15.3% after the company said CMS reversed earlier Medicare billing/fee-schedule changes for non-invasive bone growth stimulators, restoring reimbursement to prior levels. CMS issued revised guidance July 1, 2026, withdrawing modifications tied to HCPCS codes. The stock moved from near $8.85 toward $11.46; insiders sold about $2.7M over three months.